Background: Combined oral contraceptive (COC) use reduces epithelial ovarian cancer (EOC) risk. However, little is known about risk with COC use before the first full-term pregnancy (FFTP).
Combined oral contraceptive (COC) use is an established factor that consistently reduces the risk for epithelial ovarian cancer (EOC; Beral et al, 2008) . Less is known about the association between EOC risk and COC use with respect to the timing of fullterm births. Increasing parity reduces EOC risk (Hankinson and Danforth, 2006) , but it is difficult to tease apart the independent effects of COC use and parity. The total number of ovulatory years between menarche and menopause has been used, but this does not address the timing of COC use with respect to full-term births. Studies of breast cancer (Schlesselman, 1989; Romieu et al, 1990; Kahlenborn et al, 2006) and endometrial cancer (Cook et al, 2014) have reported a long-term effect with the use of COCs before the first full-term pregnancy (FFTP) among parous women. We therefore investigated the EOC risk associated with COC use, focusing on COC use before the FFTP.
MATERIALS AND METHODS
This Canadian population-based case-control study has been previously described (Cook et al, 2016) including ethics approvals (Conjoint Health Research Ethics Board, Calgary, Alberta (AB) and Research Ethics Board, British Columbia (BC) Cancer Agency, Vancouver, BC) and written informed consent. Briefly, cases were identified from the population-based BC and AB cancer registries who were: age 20-79 years (40-79 in AB); diagnosed with first primary, incident, histologically confirmed EOC (invasive EOC in AB); and able to complete study in English. A total of 1505 cases (60% of 2522 eligible) completed the study. Eligible controls identified from provincial health rosters and a mammography screening program (Eheman et al, 2014) were: aged 20-79 years (40-79 in AB); able to complete study in English; and, had at least one ovary. A total of 2564 (53% of 4838 eligible) completed the study.
Risk factor information was ascertained through the diagnosis date (month/year) for cases and an assigned reference date (month/year) for controls based on an age-frequency match with cases. Respondents completed a self-administered questionnaire (BC before 2005) or a telephone interview (AB and BC after 2005) . In additional to demographic, lifestyle, and medical/reproductive factors, women provided information on COC use, including dates or ages of use. Specific COC names were not ascertained. Histotypes were determined by re-review of haematoxylin and eosin slides according to contemporary criteria (Köbel et al, 2014) for 979 women (85.6%).
The analysis was restricted to those X40 years of age at diagnosis/reference date (1144 invasive cases and 2513 controls). Combined oral contraceptive use was evaluated as: non-use (never or o0.5 years) vs ever use (X0.5 years); continuous duration (years, ever users only) and, as categorical duration (non-use, o5 years, 5-10, X10 years, and unknown). We used logistic regression to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) in R software (R Development Team, 2015) . All variables in Table 1 after 2005, and 40-49, 50-59, 60-69, X70 years of age), parity (0, 1, 2, X3 or 1, 2, X3 when restricted to parous women), age at FTTP (p24, 25-29, X30 years), breastfeeding (never, ever), first degree family female breast or ovarian cancer (no, yes), tubal ligation (no, yes), and BMI (o25, 25-29.9, 30-34.9, X35 kg m À 2 ). Other variables did not alter the estimated ORs by more than 10%. Histotype-specific analyses were restricted to high-grade serous and combined endometrioid/clear cell, due to few cases of other histotypes. Because COC use exclusively before and exclusively after the FFTP were mutually exlcusive, they were modelled simultaneously, allowing direct comparisons of the two risk estimates using contrasts (Montgomery, 2012) .
RESULTS
Characteristics of parous cases and controls are described in Table 1 . Combined oral contraceptive use was common among parous women, reported by 61% of cases and 80% of controls. With respect to the timing of COC use ( exclusive use before the FFTP was compared (via contrasts) with the risk estimate for exclusive use after, the aORs were found to be significantly different (P-value, o0.01) ( Table 2 ).
When we stratified by age at FFTP, COC use before and after as well as exclusively before the FFTP was consistently associated with a reduction in EOC risk regardless of age at first birth, a consistency that was not seen with COC use exclusively after the FFTP (Figure 1) , although some results were unstable. Similar results were noted when stratified by parity, although risk estimates were more similar for parity X3 (Figure 1) .
The association of COC use and EOC risk for our entire study population (both parous and non-parous women combined) was consistent with the reported literature (Supplementary Tables 1-4 ). Any COC use was associated with a reduction in risk (aOR ¼ 0.58, 95% CI ¼ 0.49, 0.69). Among COC users, risk was most strongly reduced with longer durations of use overall, within more recent time since last use, and for younger ages at first use. 
CONCLUSION
When we assessed the timing of COC use exclusively before the FFTP among parous women, we found a strong reduction in risk (B40%), which was almost as strong as the B50% risk reduction seen with COC before and after the FFTP. Even for fairly shortterm COC use (o5 years) before the FFTP there was a significant and substantial reduction in risk years later in parous women. This result is surprising, given that these women all experienced the reduction in risk associated with being parous, and given that the literature (Beral et al, 2008) and our own results for parous and non-parous women indicating that last use of COCs in the more distant past is associated with weaker reductions in risk. In contrast, the effect of such use after the FTTP was of lesser magnitude, despite the assumption that the cessation of ovulation in these women should have equivalent effects regardless of the timing of COCs. Consistent with our findings, other studies have reported that any use of COCs before age 20 years (Ness et al, 2000; Kumle et al, 2004; Beral et al, 2008; Lurie et al, 2008) or 25 years (Bosetti et al, 2002) is associated with a reduced EOC risk of 29-50% many years later. Ours is the first study to assess COC use exclusively before and after the FFTP to evaluate the timing of COC use with pregnancy.
Although the more immediate effects of COC use on biological end points such as hormone levels, gene expression, and ovulation are well documented, the long-term effects on EOC risk are largely attributed to fewer ovulations during reproductive life (Fathalla, 1971) , with the assumption that the timing of ovulation reduction does not matter. Our results could be due, in part, to fewer ovulations because of COC use, but it is not clear why use before the FFTP would have such a strong, lasting impact on EOC risk. In breast cancer, the elevated risk noted with COC use before the FFTP has been hypothesised to be related to the carcinogenic susceptibility of undifferentiated breast tissue at this time (Romieu et al, 1990) , and in endometrial cancer the reduction in risk with early COC use is unknown but may be related to a lasting effect on hormone levels that reduce cellular proliferation (Chan et al, 2007) . Whether such mechanisms are also applicable to a long-lasting reduction in EOC risk is not clear. Regardless of the tissue of origin for EOC (fallopian tube, endometrium, ovary, etc.), our results suggest that the timing of ovulation reduction is important, and that there may be other long-term mechanisms for an EOC risk reduction beyond ovulation that manifest before the FFTP.
Study strengths include the population-based design; large sample size; restriction to first primary, histologically confirmed invasive EOC; detailed information on parity; assessment of contemporary histotypes (Köbel et al, 2014) ; high prevalence of COC use; and, restriction to parous women with adjustment for parity, thus minimising confounding by parity. Limitations include: no COC name/dosage information; cases recalling past COC use more fully than controls (but that would bias risk estimates to the null value); relatively low response percentage among the control women; and, possible residual confounding. In addition, COC use in this study represents formulations of COC available in the past, and current formulations may not have the same long-term effects. In summary, the significant reduction in EOC risk observed with COC use before the FFTP among parous women is a novel and requires replication. Despite the consistently reported risk reduction in EOC with COCs, questions remain about the timing of use and the underlying biological mechanisms of long-term effects to guide future EOC risk prediction (Pearce et al, 2015) and directed chemoprevention strategies for high-risk women (Walker et al, 2015) .
